Innovent-Pfizer deal makes joint development, commercialization pillar in biotech global push
A researcher seen at an Innovent Biologics lab in Suzhou, Jiangsu province. YANG HAISHI/FOR CHINA DAILY The $10.5 billion partnership announced by Chinese innovative biotech Innovent Biologics and US pharmaceutical giant Pfizer in late May highlights an emerging shift in cross-border biotech dealmaking, with some Chinese drug developers moving beyond traditional out-licensing arrangements toward partnerships…









